Send to

Choose Destination
Cardiovasc Radiat Med. 2003 Oct-Dec;4(4):182-5.

Postprocedural low molecular weight heparin in patients at high risk of subacute stent thrombosis.

Author information

Roy and Ann Foss Interventional Cardiology Research Program, Terrence Donnelly Heart Center, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.



Subacute stent thrombosis (SAT) is a dramatic complication of percutaneous coronary stenting occurring in 0.4-20% of cases depending on several angiographic and clinical variables. The role of postprocedural low molecular weight heparin (LMWH) in preventing early events after high-risk PCI is not well established. In this study we describe our experience with postprocedural LMWH in patients deemed to be at high risk of SAT.


Thirty-six patients who were treated with subcutaneous LMWH for at least 7 days after the intervention were identified from our database. All cineangiograms and charts were retrospectively reviewed to confirm the high-risk intervention properties. Thirty-day and long-term major adverse coronary events (MACEs) were documented in all patients.


The most common indications for LMWH were the deployment of > or =3 consecutive stents, the presence of intracoronary thrombus or ulceration, poststenting residual stenosis, contraindication to aspirin or thienopyrideines, and persistent dissection. The majority of patients (61%) had > or =2 risk factors. Mean postprocedural treatment period was 12+/-3 days. At 30 days, none of the patients experienced a MACE including death, myocardial infarction, and repeat revascularization. No major bleeding occurred and one patient (2.7%) had a minor bleeding. At a mean follow-up of 31 months, MACE occurred in 17% of patients.


Postprocedural LMWH is safe and effective in preventing SAT in patients undergoing high-risk coronary intervention.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center